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Screening for pre-eclampsia: a systematic review of tests combining uterine artery Doppler 
with other markers 
 
SHORT TITLE 







To perform a systematic review of screening for pre-eclampsia (PE) with the 
combination of uterine artery Doppler (UAD), maternal history, mean arterial pressure and/or 
maternal serum markers. 
Methods 
We identified eligible studies through a search of Medline, and, for each included study, 
we assessed the risk of bias and extracted relevant data. We reported the performance of 
screening tests according to the target population (low or high-risk), the trimester of screening 
(first and/or second) and the subset of PE screened for (early and late). 
Results 
Several tests provided moderate or convincing prediction of early PE, but screening for 
late PE was poor. Although UAD is more accurate in the second-trimester, we found 
encouraging results for first-trimester screening when it was combined with other markers. 
Performance of screening was consistently lower in populations with risk factors for PE in the 
maternal history.  
Conclusions 
We present encouraging results for the prediction of early PE, even in the first-trimester 
of pregnancy. The different performance of tests in screening for early versus late PE, and of 
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Pre-eclampsia (PE) affects 2-8% of pregnancies and is a major cause of maternal and 
perinatal morbidity and mortality [45]. In mothers, PE may lead to disseminated 
coagulopathy, pulmonary edema, renal or liver failure, eclampsia, stroke and placental 
abruption [38]. In fetuses, it may cause intrauterine growth restriction (IUGR), hypoxia-
neurologic injury and preterm delivery [38]. Ultimately, PE may lead to death of the mother 
and/or the fetus [38].   
Considering the impact of PE in obstetrics, the development of an accurate screening 
method would be of great value. Although, at present, there is no effective preventive 
intervention for PE [38,45], screening would allow us to select a group of pregnant women 
who would receive increased maternal and fetal monitoring [12]. From a research point of 
view, it would be essential for future development of effective prophylactic measures, as it 
would enable the recruitment of high-risk women in which the effect of those measures could 
be evaluated [12]. 
Classically, PE has been associated with inadequate trophoblast invasion of the spiral 
arteries and consequent failure of development of a low-resistance uteroplacental circulation 
that characterizes normal pregnancies [10,13]. Therefore, uterine artery Doppler (UAD) has 
been extensively studied as a screening test for PE. A recent meta-analysis [11] reported that a 
high second-trimester pulsatility index (PI) detects 42% of PE cases with a specificity of 91%. 
In the first-trimester, the accuracy is lower, with a sensitivity of 25% and a specificity of 95%. 
The National Institute for Health and Clinical Excellence [24] currently recommends 
the assessment of each woman’s risk for PE on the basis of maternal history. Age ≥ 40 years, 
body mass index ≥ 30 Kg/m
2
, pre-existing vascular or renal disease, nulliparity or pregnancy 
interval of > 10 years, prior or family history of PE and multiple pregnancy increase the 
probability of developing PE. However, accuracy of screening with maternal history alone is 
low [32]. 
In addition to UAD and maternal history, a large number of maternal serum markers 
have been investigated for the prediction of PE, but their use as single screening tests has also 
been disappointing [6]. Finally, early measurement of mean arterial pressure (MAP) is 
another screening test that should not be forgotten because it is simple and inexpensive and 
appears to be an important predictor of subsequent PE [6].  
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Despite great research efforts, in 2004, the World Health Organization [12] concluded 
that no single test was yet available to provide accurate screening for PE. Since then, there has 
been growing interest in the combination of markers for PE screening. Recently, this was 
reviewed by Giguère et al. [17], who concluded that the combination of biochemical and 
ultrasonographic markers improves prediction of PE. However, the authors did not 
systematically evaluate the contribution of maternal history and MAP to combined screening.  
In this context, we performed the current systematic review to evaluate first and second-
trimester screening for PE with tests that combine UAD with maternal history, MAP and/or 







A search was conducted in the Medline database using the following MeSH terms or 
keywords, with no limits:  
preeclampsia, pre-eclampsia, diagnosis, screening, prediction, uterine artery, Doppler, 
clinical, maternal, characteristics, factors, history, blood pressure, pregnancy-associated 
plasma protein-A, PAPP-A, chorionic gonadotropin, hCG, alpha-fetoprotein, inhibin A, 
activin A, placental protein 13, placental growth factor, soluble fms-like tyrosine kinase 1, 
soluble vascular endothelial growth factor receptor-1. 
Additional keywords were tested but were not included in the final query because they 
did not improve the sensitivity of the search. 
Table 1 presents the selection criteria used to determine the eligibility of the studies 
identified by the search, and, when appropriate, the rationale for using those criteria. They 
were applied in two stages: first, to the titles and abstracts of the articles yielded by the query; 
second, to the full texts of the articles selected in the first stage.  
The reference list of the selected articles was also searched to identify additional 
potential articles of interest, which were then retrieved and submitted to the selection criteria. 
The search was updated periodically and was last run on 10 December 2010.  
Relevant data were extracted from each article using a standardized form. Risk of bias 
was assessed according to criteria that had been previously used [12] and that we adapted to 
our own review (Table 2). In nested case-control studies, we considered selection adequate 
when cases included “all (or a representative sample of) individuals with the outcome of 
interest occurring in the defined cohort” and controls were “a random sample of the 
individuals remaining in the cohort”
 
[47]. This way, investigators ensured that cases were 
representative of individuals with the outcome in the population studied and that controls 
were representative of individuals without the outcome in the same population.  
When available, we reported the following measures of accuracy: area under the ROC 
curve (AUC), specificity (Sp), sensitivity (Sn), and likelihood ratios of the positive (LR+) and 
negative (LR-) results. The LR+ is defined as Sn/(1-Sp) and the LR- as (1-Sn)/Sp [12]. 
Convincing prediction is provided by tests with LR+ > 10 and LR- < 0.1 [11,12]. On the other 
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hand, tests with LR+ < 5 or LR- > 0.2 achieve only minimal prediction and the other tests 
achieve moderate prediction [12].  
We followed the PRISMA guidelines [22] in order to maximize the quality of the report 







Figure 1 depicts the results of each stage of the selection process. According to the 
selection criteria previously described, 35 articles were eligible and, of those, three [34,36,37] 
reported results of the same cohort. Therefore, 33 studies were reviewed, which are described 
in Table 3. 
Twenty-one cohort and 12 nested case-control studies were included. Seven were 
conducted in high-risk populations, defined by the presence of risk factors for PE in the 
maternal history, an abnormal second-trimester UAD or high second-trimester levels of 
human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP).  
Studies of low-risk populations reported a prevalence of PE that varied between 1.2% 
and 10.5%, although it was ≤3.0% in the majority. Those which evaluated screening for early 
PE reported a prevalence of this outcome of 0.3%-0.8%, with the exception of one study 
which reported a prevalence of 2.3%.  
The conclusions of some studies are limited by the size of their samples, which is partly 
related to the low frequency of PE and especially early PE in the general population. For 
example, six studies included only ≤10 participants with early PE.  
Screening tests were performed in the first-trimester in 12 studies, in the second-
trimester in 15 and in both trimesters in six.  
Maternal history was evaluated in 16 studies, pregnancy-associated plasma protein-A 
(PAPP-A) in 11, inhibin A in nine, placental growth factor (PlGF) in eight, hCG, activin A 
and placental protein 13 (PP13) in six each, soluble fms-like tyrosine kinase 1 (sFlt1) in four, 
MAP and AFP in three each.  
It should be noted that some studies are related. Seven of them [1-3,30,33-35] were 
conducted as part of the same research program and had overlapping study groups. This also 
happened in two additional studies [27,49]. To avoid data duplication, whenever a screening 
test was evaluated in more than one of these studies, we only reported its performance in the 
study with the largest sample. Other studies [40 and 44, 42 and 43] also had common 




Figure 2 presents the results of the assessment of the risk of bias. Selection of the study 
participants was generally adequate but occasionally inadequate or unreported. The study 
population was adequately described in nearly all studies whereas description of the screening 
tests was frequently inadequate because the selected cut-off points were not specified. 
Blinding of the readers of the screening tests was usually adequate, but sometimes unreported. 
On the other hand, complete blinding of the readers of the reference standard was 
accomplished in only two studies and was inadequate or unreported in the remaining. Follow-
up and verification was adequate in most studies but in several it was unreported.  
Tables 4, 5, 6 and 7 summarize the results of each study. The performance of screening 
tests is reported quantitatively, through AUC, Sp, Sn, LR+ and LR-, and qualitatively, 
through a citation of the article. 
Figures 3 and 4 show the screening tests that provided moderate or convincing 
prediction, according to the LR values. None of the screening tests for late PE qualified. A 
few screening tests for total PE were moderately predictive, all of which involved second-
trimester testing. On the other hand, screening for early PE was accomplished with moderate 
accuracy by several first and second-trimester tests. Additionally, four tests were on the verge 







Best first-trimester screening tests for early PE  
Our results suggest that, in the first-trimester, accurate screening for early PE probably 
requires the combination of several markers. Two tests that combined UAD with four other 
markers had a very good performance.  
The combination of mean-PI (M-PI), maternal history, MAP, PAPP-A and PlGF was 
highly predictive of early PE, in a nested case-control study with almost 30 cases of early PE 
[33]. Of the 33 studies reviewed, one included the same number of early PE cases and only 
six included a higher number. Unfortunately, there were additional cases of early PE in the 
original cohort who did not have available serum for the measurement of PlGF and thus were 
not included in the case-control study. Although selection of cases was simply based on 
serum availability, we cannot be certain that the sample is representative of the original 
population. We conclude that these results are very encouraging but require confirmation by 
future studies. 
The other test combined lowest-PI (L-PI), maternal history, PAPP-A, inhibin A and 
PlGF and was applied to a cohort of nulliparous women [8]. However, it should be considered 
with caution because the cohort included only four participants who subsequently developed 
early PE. Furthermore, the authors reported that L-PI was not significantly different between 
the PE and normal outcome groups and that it did not improve screening by maternal history 
combined with the three serum markers.  
Several other tests had a good performance in the first-trimester, virtually all of them 
with a LR+ > 8.6 and a LR- ≤ 0.18. The majority took into account the maternal history. 
Other markers frequently considered were MAP, PAPP-A, inhibin A and PlGF. In particular, 
we’d like to highlight that screening with L-PI, maternal history, MAP and PAPP-A achieved 
a LR+ of 9.46 and a LR- of 0.06, in a cohort of over 8300 women, including 37 with early PE 
[34,36,37].   
One study [25] also achieved promising results with the combination of M-PI and PP13, 
albeit in a sample that included only ten early PE cases. These results are supported by other 
studies, which demonstrated that first-trimester PP13 is a significant predictor of early PE [2] 
and that it improves screening with first [21] and second-trimester UAD [41]. However, one 
study did not confirm the predictive accuracy of PP13 [8]. 
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Best second-trimester screening tests for early PE  
Screening for early PE in the second-trimester probably requires the combination of 
fewer markers, as UAD alone is substantially more accurate when performed in this trimester 
[11].  
The association of M-PI, maternal history and MAP almost provided convincing 
prediction in a cohort of over 3000 women, including 23 with early PE [26]. The same 
promising results were obtained when maternal history and first-trimester UAD were 
combined with the assessment of the ratio between M-PI in the second and first trimesters, in 
a cohort of similar dimensions [31]. Therefore, measurement of maternal serum markers may 
not be necessary to provide accurate screening for PE in the second-trimester, because the 
combination of UAD with the simple and inexpensive evaluation of maternal history and 
MAP may be sufficient. 
In women with abnormal second-trimester UAD, sFlt1 appeared to be useful in early PE 
screening. In one study [14], sFlt1 provided moderate prediction and the sFlt1/PlGF ratio 
almost provided convincing prediction. A similar study [46] demonstrated a good 
performance of the two serum markers when they were concurrently measured but not 
combined in a ratio. However, both studies were limited by the size of their samples, which 
included only 8 and 9 women with early PE, respectively. Moreover, their results were 
challenged by a larger study, which found that sFlt1 was not able to predict early PE in a 
group of women with abnormal UAD [15]. 
In one second-trimester study [40], combination of UAD and PP13, with or without 
other serum markers, achieved moderate prediction of early PE (LR+=5, LR-=0). However, 
this was a case-control study which included only five cases of early PE that were selected 
from a cohort on the basis of serum availability. Furthermore, the authors reported that the 
addition of PP13 to UAD did not improve screening. 
Best screening tests for late and total PE 
In contrast with early PE, none of the tests were even moderately predictive of late PE. 
On the other hand, prediction of total PE was accomplished with moderate accuracy by some 
tests, all of which involved second-trimester screening and combined UAD with inhibin A, 




What to screen? Early versus late PE 
The performance of screening tests was consistently and substantially better in the 
prediction of early PE, comparing to late PE. Our results support the concept that these are 
distinct disease entities [20,48], with impaired placentation and defective angiogenesis being 
related especially to early PE [13,14,45], and cardiovascular and metabolic risk factors 
probably leading to late PE [45]. Although much less frequent than the late form of the 
condition [20], early PE is the main contributor to the maternal and perinatal morbidity and 
mortality seen in PE [1,31], as it is associated with premature delivery, a higher risk of IUGR, 
more severe maternal disease and a higher rate of pregnancy-related maternal death [20,48]. 
Considering its impact, the low incidence of early PE should not prevent routine screening. 
Moreover, trisomy 21, for which screening is currently performed, is even less frequent, 
affecting only 0.14% of newborns in the absence of any intervention [24]. 
When to screen? First versus second-trimester screening 
Even though UAD is more accurate in the second-trimester [11], we found encouraging 
results for first-trimester screening when it was combined with other markers. We believe that 
screening for PE is most relevant in the first-trimester because, as suggested by a recent meta-
analysis [10], preventive interventions are more likely to be effective if initiated early in 
pregnancy, when pathogenic mechanisms can still be modified. 
Who to screen? Low versus high-risk populations 
Three studies evaluated the performance of screening tests in high-risk populations 
characterized by the presence of certain risk factors in the maternal history. 
Screening a preselected high-risk population is of particular interest when the condition 
screened is infrequent, as is the case of early PE. Assuming that the sensitivity and specificity 
of the screening test remain constant, the positive predictive value increases when it is applied 
to a population with higher disease prevalence. 
Interestingly, however, the accuracy of screening tests was consistently lower in the 
previously mentioned studies than in studies of low-risk populations. In nulliparous women 
[8], the performance of screening with L-PI and maternal history was poorer than in 
unselected pregnancies [34,36,37].  In women with risk factors such as chronic hypertension, 
pregestational diabetes mellitus and obesity, screening with M-PI and maternal history [19] or 
with M-PI and PP13 [21] was also less predictive than in low-risk populations [31,25]. 
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In the meta-analysis performed by Cnossen et al. [11], screening with the pulsatility 
index was less accurate in high-risk populations. Thus, our results may be explained by the 
lower performance of UAD in women with historical risk factors. They further support the 
concept of PE as a heterogeneous disease [13,38,48] and suggest that, in these women, 
impaired placentation may play a less important role in the development of PE [19].  
Limitations of the reviewed studies 
Several studies that we reviewed were limited by the size of their samples and by the 
risk of bias in certain methodological areas.  
Selection of study participants was occasionally inadequate. Some nested case-control 
studies included only a subset of PE cases of the original cohort because only those had 
available blood samples for the measurement of specific markers. Additionally, some cohort 
studies did not apply the screening tests to all eligible participants. 
Outcome assessors were not completely blinded to the results of the screening tests in 
several studies. In some cases, blinding was inadequate because the results of UAD 
influenced the subsequent management of pregnancies. In other cases, investigators evaluated 
screening for PE with first-trimester PAPP-A or hCG, or with second-trimester hCG or AFP, 
and had to communicate the results of the screening tests to pregnant women and their 
managing clinicians because they were necessary for routine assessment of trisomy 21 risk. 
This shows that, at times, although the methodology of the study may lead to bias, it is the 
best that researchers are able to do, and for that reason the PRISMA statement [22] 
recommends that the term “quality” be replaced by “risk of bias”. 
The comparison of individual studies is limited by differences observed among them, 
concerning, for example, the definitions of PE and early PE and the UAD technique. 
Although, in the studies reviewed, the definitions of PE always included the concurrent 
presence of hypertension and proteinuria, we identified among them several differences. 
Concerning hypertension, some studies considered it to be present when either the systolic 
(SBP) or diastolic (DBP) blood pressure (BP) was elevated, while others did so only in the 
presence of high DBP. Generally, the diagnosis of hypertension required at least two 
recordings of elevated BP with a minimal 4-6 hour interval, and cutoffs of 140 mmHg and 90 
mmHg were considered for high SBP and DBP, respectively. Occasionally, however, studies 
reported the presence of hypertension when DBP was ≥ 110 mmHg on any occasion or ≥ 90 
mmHg on at least two occasions. Proteinuria was usually defined as protein excretion of        
14 
 
≥ 300 mg in a 24-hour urine collection, but two dipstick readings of ≥ 2+, or occasionally      
≥ 1+, were also frequently considered diagnostic if no 24-hour collection was available.  
The definition of early PE was also not uniform and almost one third of the studies did 
not report screening for this outcome. 
The technical performance of UAD was usually but not always clearly reported. 
Investigators used color Doppler to identify the uterine arteries (UA) and pulsed wave 
Doppler to obtain the flow velocity waveforms. In the first-trimester, UAD was generally 
performed using a transabdominal approach. In the second-trimester, transabdominal UAD 
was also used, but the transvaginal approach was more frequent, often because investigators 
concurrently measured the cervical length for the assessment of the risk of premature 
delivery. In the majority of studies, waveforms were obtained from the UA at the level of the 
internal cervical os but in several others they were obtained at or one centimeter distal to the 
crossover point with the external iliac artery. Investigators variably required an angle of 
insonation below 30º, 50º or 60º, and several did not describe it. Although PI was most 
frequently reported, some studies evaluated other Doppler parameters, such as the resistance 
index or the presence of early diastolic notches.   
Limitations and strengths of our review 
The strength of our conclusions is limited by the multiplicity of combinations evaluated, 
the variability of the gestational age at which tests were performed (even within the same 
trimester) and the diversity of populations studied. Additionally, as in any review, it is limited 
by the shortcomings of the original studies, which we have previously discussed. 
On the other hand, our review has several strengths: we used explicit and reproducible 
methodology; we minimized the risk of bias using rigorously predefined selection criteria and 
a standardized data extraction form; we assessed the risk of bias of the included studies with 
objective criteria; we reported the findings of each study and summarized those findings in a 
systematic way.  
Our review does not provide definitive conclusions but rather highlights important 
advances that have been made in PE screening and offers guidance and optimism for future 
research. To our knowledge, it is the first review that systematically evaluates the 
combination of UAD, maternal history, MAP and serum markers in the prediction of PE. 
While screening for total and especially late PE remains disappointing, we have 
demonstrated encouraging results in the prediction of early PE. In addition to the eight serum 
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markers we reviewed, others, such as soluble endoglin and homocysteine, might be useful 
when combined with UAD. 
We believe that future research should focus on first-trimester screening for early PE, 
with a combination of UAD, maternal history, MAP, and serum markers such as PAPP-A, 
inhibin A and PlGF. Large cohort studies are needed in order to accurately study this 
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Table 1 – Selection criteria used to determine eligibility of the studies for the systematic review. 
Inclusion criteria 
1. Study design Prospective studies, in which screening tests were applied before outcomes were developed, including 
cohort and nested case-control studies. 
Rationale A case-control design may represent a valid alternative to a cohort analysis if cases and controls 
belong to a common reference population; otherwise, selection bias may ensue. This is assured when 
participants are selected from a well defined cohort, as in nested case-control studies, which take 
advantage of “both the methodologic soundness of the cohort design (i.e., limiting selection bias) and 
the efficiency of the case-control approach” (limiting costs). [47] 
2. Study aim To evaluate the performance of screening tests. 
3. Screening test Combination of UAD and one or more of the following: maternal history, MAP, PAPP-A, hCG, AFP, 
inhibin A, activin A, PP13, PlGF, sFlt1. 
4. Trimester of screening First (0 to 13+6 weeks’ gestation) and/or second (14+0 to 27+6 weeks’ gestation). 
5. Condition screened Early and late PE, ideally. 
Total PE, in alternative. 
Other subtypes of PE (e.g., severe PE), if none of the previously referred outcomes were considered. 
Rationale According to von Dadelszen et al. [48], gestational age at onset of PE “is the most important clinical 
variable in predicting both maternal and perinatal outcomes”.  
6. Population screened Low-risk population: recruitment of participants from an unselected obstetric population; 
or 
High-risk population: recruitment of (1) women with risk factors for PE in their clinical history (e.g. 
chronic hypertension) or (2) women with a positive result in a previous screening test (e.g. women 
with abnormal UAD). 
7. Reference standard Several definitions of PE were accepted, as long as they included the concurrent presence of 
hypertension and proteinuria. 
Several definitions of early PE were accepted, but the preferred one was: PE requiring delivery before 
34 weeks’ gestation. When other definitions were considered, they were specified. 
Rationale The selection of the preferred definition of early PE was based on the following facts: (1) the 
administration of glucocorticoids is recommended for fetal lung maturity when there is risk of 
preterm delivery in pregnant women with less than 34 weeks’ gestation [18]; (2) preterm birth 
occurring after 34 weeks’ gestation is rarely associated with mortality or major morbidity [18]. 
Exclusion criteria 
 The definition of PE considered in the study was not reported. 
 PE was combined with other pregnancy complications in the outcome. 
PE: pre-eclampsia; UAD: uterine artery Doppler; MAP: mean arterial pressure; PAPP-A: pregnancy-associated plasma protein-A, hCG: human 
chorionic gonadotropin; AFP: alpha-fetoprotein; PP13: placental protein 13; PlGF: placental growth factor; sFlt1: soluble fms-like tyrosine kinase 1. 
 
  
Table 2 – Criteria for assessment of risk of bias. 
1. Selection of study participants 
 Adequate  Cohort studies in which all eligible women were included consecutively or randomly into the 
study. 
 Nested case-control studies in which all eligible women were included consecutively or 
randomly into the original cohort, all or a random selection of the participants that developed PE 
in the original cohort were included as cases, and a random selection of the unaffected 
participants of the original cohort were included as controls. 
 Inadequate  Studies which did not meet at least one of the above-mentioned criteria. 
 Unreported  It was not possible to draw a conclusion based on the information reported in the article. 
2. Description of the study population 
 Adequate  Two or more of the following characteristics were described: women’s age, parity, underlying 
diseases or the risk status of the population (low or high). 
 Inadequate  Only one or none of the above-mentioned characteristics was reported. 
3. Description of the screening tests 
 Adequate  Cut-off levels, clear definitions of positive and negative test results, and gestational age at which 
the screening tests were performed were mentioned in the text. 
 Inadequate  Absence of any of the above-mentioned information in the report. 
4. Blinding of the readers of the screening tests 
 Adequate  Readers of all the screening tests were masked to the results of the reference standard. 
 Inadequate  Readers of at least one of the screening tests were not masked to the results of the reference 
standard. 
 Unreported  It was not possible to draw a conclusion based on the information reported in the article. 
5. Blinding of the readers of the reference standard 
 Adequate  The results of the screening tests were not communicated to the managing clinicians and readers 
of the reference standard were masked to the results of the screening tests. 
 Inadequate  The results of at least one of the screening tests were communicated to the managing clinicians 
or readers of the reference standard were not masked to the results of the screening tests. 
 Unreported  It was not possible to draw a conclusion based on the information reported in the article. 
6. Follow-up and verification 
 Adequate  At least 90% of the participants originally subjected to the screening tests were followed up and 
had verification by the reference standard. 
 Miscarriage, fetal abnormalities and multiple pregnancies were regarded as legitimate 
exclusions. 
 Inadequate  Less than 90% of the participants originally subjected to the screening tests were followed up. 
 Unreported  It was not possible to draw a conclusion based on the information reported in the article. 








  42 articles retrieved for further evaluation 
Screening of titles and abstracts 
156 articles identified by the electronic search 
114 articles excluded 
Screening of reference lists 
6 articles retrieved for further evaluation 
48 articles in total retrieved for further evaluation 
 
13 articles excluded because: 
The article was a letter to the editor (2 articles) 
The performance of a screening test was not evaluated  
(3 articles) 
The screening test evaluated included at least one marker 
that was not considered in our review (1 article) 
The definition of pre-eclampsia used in the study was 
not reported (2 articles) 
The outcome evaluated was pre-eclampsia combined 
with other pregnancy complications (5 articles)  
 
35 articles included in the systematic review 




















































Figure 2 – Assessment of the risk of bias. 
Table 3 – Description of the studies included in the systematic review. 
Reference, study design and sample characteristics 
We report the total number of participants of the cohort (N), the number of 
participants with each outcome and, in parentheses, the prevalence of each 
outcome in the cohort. 
Tests performed Time of 
testing 
(weeks) 
Akolekar R et al., 2009 [1]
 
Nested case-control 
UAD, maternal history,   
PAPP-A, inhibin A 
11-14 
Cohort: N=8234, 147 (1.8%) PE, unreported early PE 
Cases and controls: 121 PE, 26 early PE, 208 controls 
Akolekar R et al., 2009 [2] 
Nested case-control 
UAD, maternal history,   
PAPP-A, PP13 
11-14 
Cohort: N=15759, 298 (1.9%) PE, unreported early PE 
Cases and controls: 208 PE, 48 early PE, 416 controls 
Akolekar R et al., 2008 [3]
 
Nested case-control 
UAD, maternal history,   
PAPP-A, PlGF 
11-14 
Cohort: 1.8% PE, other characteristics were not described 
Cases and controls: 127 PE, 29 early PE, 609 controls 
Alkazaleh F et al., 2006 [4]
 
High-risk cohort (high 2nd trimester hCG and AFP) 





Aquilina J et al., 2001 [5]
 
Cohort 





Audibert F et al., 2005 [7]
 
Cohort 





Audibert F et al., 2010 [8]
 
High-risk cohort (risk factors in maternal history)  
UAD, maternal history,   




Total cohort** N=893, 40 (4.5%) PE, 9 (1.0%) early PE* 
Cohort with PlGF 
measurement** 
N=531, 22 PE (4.1%), 4 (0.8%) early PE* 
Ay E et al., 2005 [9]
 
Cohort 
N=178, 14 (7.9%) PE 




Diab AE et al., 2008 [14]
 
High-risk cohort (abnormal 2nd trimester UAD) 
N=108, 33 (30.6%) PE, 8 (7.4%) early PE 
UAD, PlGF, sFlt1 23 
Espinoza J et al., 2007 [15]
 
Cohort 
N=3296, 113 (3.4%) PE, 15 (0.5%) early PE 
UAD, PlGF, sFlt1 22-26 
Florio P et al., 2003 [16]
 
High-risk cohort (abnormal 2nd trimester UAD) 
N=58, 18 (31.0%) PE 
UAD, inhibin A, activin A 
 
24 
Herraiz I et al., 2009 [19]
 
High-risk cohort (risk factors in maternal history) 
N=152, 20 (13.2%) PE, 7 (4.6%) early PE 
UAD, maternal history 11-14 
Khalil A et al., 2010 [21]
 
Nested case-control (in high-risk cohort with risk factors in maternal history)  
UAD, PP13 11-14 
Cohort: N=395, 42 (10.6%) PE, 14 (3.5%) early PE 
Cases and controls: 42 PE, 14 early PE, 210 controls 
Llurba E et al., 2009 [23]
 
Cohort 
N=6035, 75 (1.2%) PE, 20 (0.3%) early PE† 
UAD, maternal history 19-22 
Nicolaides KH et al., 2006 [25]
 
Nested case-control 
UAD, PP13 11-14 
Cohort: Not described 
Cases and controls: 10 early PE, 423 controls 
Onwudiwe N et al., 2008 [26]
 
Cohort 
N=3347, 101 (3.0%) PE, 23 (0.7%) early PE 
UAD, maternal history, MAP 22-24 
Papageorghiou AT et al., 2005 [27]
 
Cohort 
N=16806, 369 (2.2%) PE 
UAD, maternal history 22-24 
Parra M et al., 2005 [28]
 
Nested case-control  
UAD, PlGF, sFlt1 
UAD, PlGF, sFlt1 
11-14 
22-25 Cohort: N=743, 33 (4.4%) PE 
Cases and controls: 33 PE, 137 controls 
(8 PE and 37 controls with 1st trimester screening;  
26 PE and 100 controls with 2nd trimester screening) 
Pilalis A et al., 2007 [29]
 
Cohort 
N=878, 13 (1.5%) PE 
UAD, maternal history,   
PAPP-A 
11-14 
Plasencia W et al., 2007 [30]
 
Cohort 
N=6015, 107 (1.8%) PE 
UAD, maternal history 11-14 
Plasencia W et al., 2008 [31]
 
Cohort 
N=3107, 93 (3.0%) PE, 22 (0.7%) early PE 




Poon LC et al., 2009 [33]
 
Nested case-control 
UAD, maternal history, MAP, 
PAPP-A, PlGF 
11-13 
Cohort: N=7797, 157 (2.0%) PE, 34 (0.4%) early PE 
Cases and controls: 127 PE, 29 early PE, 418 controls 
Poon LC et al., 2009/2010 [34,36,37] 
Cohort 
N=8366, 165 (2.0%) PE, 37 (0.4%) early PE  
UAD, maternal history, MAP, 
PAPP-A 
11-14 
Poon LC et al., 2009 [35]
 
Cohort 
N=8051, 156 (1.9%) PE, 32 (0.4%) early PE  
UAD, maternal history,   
PAPP-A 
11-14 
Simonazzi G et al., 2007 [39]
 
Cohort 
N=152, 16 (10.5%) PE 
UAD, maternal history 18-24 
Spencer K et al., 2007 [40]
 
Nested case-control 
UAD, PAPP-A, hCG, inhibin 
A, activin A, PP13  
22-24 
Cohort: Not described 
Cases and controls: 12 PE, 5 early PE‡, 73 controls 






22-24 Cohort: N=5867, 88 (1.5%) PE, 44 (0.8%) early PE‡ 
Cases and controls: 88 PE, 44 early PE‡, 446 controls 
Spencer K et al., 2008 [42]
 
Nested case-control 
Inhibin A, activin A 
UAD 
11-14 
22-24 Cohort: N=4390, 64 (1.5%) PE, 34 (0.8%) early PE‡ 
Cases and controls: 64 PE, 34 early PE‡, 240 controls 
Spencer K et al., 2005 [43]
 
Cohort 





Spencer K et al., 2006 [44]
 
Nested case-control 
UAD, inhibin A, activin A 22-25 
Cohort: Not described 
Cases and controls: 24 PE, 144 controls 
Stepan H et al., 2007 [46]
 
High-risk cohort (abnormal 2nd trimester UAD) 
N=63, 12 (19.0%) PE, 9 (14.3%) early PE 
UAD, PlGF, sFlt1 19-24 
Yu CK et al., 2005 [49]
 
Cohort  
UAD, maternal history 22-24 
Total cohort†† N=30784, 612 (2.0%) PE, 144 (0.5%) early PE 
“Model validation 
group” †† 
N=15392, 297 (1.9%) PE, 72 (0.5%) early PE 
Yu J et al., 2010 [50]
 
Nested case-control 
Inhibin A, activin A, PlGF 
UAD 
12-16 
22-24 Cohort: N=613, 31 (5.1%) PE 
Cases and controls: 31 PE, 93 controls 
PE: pre-eclampsia; UAD: uterine artery Doppler; MAP: mean arterial pressure; PAPP-A: pregnancy-associated plasma protein-A; hCG: human 
chorionic gonadotropin; AFP: alpha-fetoprotein; PP13: placental protein 13; PlGF: placental growth factor; sFlt1: soluble fms-like tyrosine kinase 
1. 
Unless otherwise specified, early PE refers to PE requiring delivery before 34 weeks’ gestation and late PE refers to PE requiring delivery at or 
after 34 weeks’ gestation. *PE diagnosed before 34 weeks’ gestation. †PE requiring delivery before 32 weeks’ gestation. ‡PE requiring delivery 
before 35 weeks’ gestation. §PE requiring delivery before 37 weeks’ gestation. ¶ Severe PE refers to PE with end-organ involvement or fetal 
growth restriction. 
**“PlGF could only be measured in 531 women, because this test was initially not scheduled and additional serum was not availab le for women 
included in the first year of the study.” [8] 
††“The cohort was divided into a model development group and a model validation group using a pseudo-random number for allocation”. [49] 
The results of this study presented in our review were estimated in the “model validation group”. 
 
  
Table 4 – Screening for PE with UAD and one other marker. 




Poon LC et al, 2009/2010 [34,36,37] | “significant contributions from a combination of (…) maternal risk factors with either the 
lowest, mean or highest (…) PI” | “Although there was no significant difference (…) screening appeared to be best with the 
lowest PI” 
L-PI + Maternal history Early 0.912 90.0 81.1 8.11 0.21 
Late 0.812 90.0 45.3 4.53 0.61 
Audibert F et al, 2010 [8] | “addition of Doppler did not improve (…) accuracy of screening by clinical characteristics alone” 
L-PI + Maternal history Early* 0.738 90.0 50.0 5.00 0.56 
Total 0.746 90.0 35.1 3.51 0.72 
Pilalis A et al, 2007 [29] | “although the difference was not statistically significant (…) the combination of (…) PI and maternal 
history (…) was better compared with (…) Doppler alone” 
M-PI + Maternal history Total 0.753 95.0 42.0 8.40 0.61 
Plasencia W et al, 2008 [31] | “effective screening (…) can be achieved by a combination of maternal variables and (…) 
Doppler” 
M-PI + Maternal history Early 0.931 90.0 77.3 7.73 0.25 
Late 0.779 90.0 42.3 4.23 0.64 
Poon LC et al, 2009/2010 [34,36,37] | See above. 
M-PI + Maternal history Early 0.902 90.0 78.4 7.84 0.24 
Late 0.813 90.0 46.9 4.69 0.59 
Herraiz I 2009 [19] | “detection rates of the combination of (…) Doppler and maternal history (…) were considerably lower 
than in the original study with low-risk pregnancies” [30] 
M-PI + Maternal history Early 0.779 90.0 42.9 4.29 0.63 
Late 0.641 90.0 23.1 2.31 0.85 
Poon LC et al, 2009/2010 [34,36,37]  | See above. 
H-PI + Maternal history Early 0.884 90.0 64.9 6.49 0.39 
Late 0.810 90.0 46.1 4.61 0.60 
Poon LC et al, 2009 [35] | “significant contributions from serum PAPP-A (…) PI (…) in the prediction of early PE” 
M-PI + PAPP-A Early 0.852 90.0 59.4 5.94 0.45 
Audibert F et al, 2010 [8] | “we did not confirm the predictive accuracy of (…) free ß-hCG” 
L-PI + hCG Not available 
Audibert F et al, 2010 [8] | “we did not confirm the predictive accuracy of (…) PP13” 
L-PI + PP13 Not available 
Nicolaides KH et al, 2006 [25] | “Effective screening (…) can potentially be provided by (…) PP-13 and (…) Doppler” 
M-PI + PP13 Early ----- 90.0 90.0 9.00 0.11 
M-PI followed by PP13 in 32% with highest risk Early ----- 84.0 90.0 5.63 0.12 
PP13 followed by M-PI in 14% with highest risk Early ----- 94.0 90.0 15.00 0.11 
Khalil A et al, 2010 [21] | “any pair combination provided better prediction than any individual marker” 
M-PI + PP13 Early 0.900 90.0 78.6 7.86 0.24 
Total 0.880 90.0 71.4 7.14 0.32 
Parra M et al, 2005 [28] | “none of the parameters assessed during the first trimester was significantly associated with PE” 
M-PI + PlGF Not available 




Llurba E et al, 2009 [23] | “combination of both methods did not significantly improve the sensitivity” 
M-PI + Maternal history Not available 
Yu CK et al, 2005 [49] | Early PE: “Ultrasound had an extremely high predictive value (…) which was not significantly 
different from the combination of maternal and ultrasound prediction” | Late PE: “the combination of ultrasound and maternal 
characteristics provided the best (…) model” 
M-PI + Bilateral diastolic notches + Maternal history Early 0.945 90.0 81.9 8.19 0.20 
Late 0.798 89.8 47.6 4.67 0.58 
  
Simonazzi G et al, 2007 [39] | “lower detection rate compared with the values stated by Yu et al.” [49] 
M-PI + Bilateral diastolic notches + Maternal history Total 0.760 90.0 50.0 5.00 0.56 
Spencer K et al, 2007 [40] | “combining (…) Doppler with (…) PAPP-A (…) did not improve detection” 
M-PI + PAPP-A Early‡ 0.800 80.0 60.0 3.00 0.50 
Late 0.520 80.0 43.0 2.15 0.71 
Audibert F et al, 2005 [7] | “[UAD combined with hCG or AFP] despite a poor sensitivity, offers a very high PPV [positive 
predictive value] in a low-risk population, multiplying the risk by 2-3 compared to Doppler alone” 
Diastolic notch + hCG Total ----- 99.53 7.84 16.68 0.93 
Ay E et al, 2005 [9] | “addition of these hormonal measurements [AFP, hCG, inhibin A, activin A] to (…) Doppler (…) does not 
cause a clinically significant improvement (…) over the use of Doppler (…) alone” 
Doppler + hCG Not available 
Audibert F et al, 2005 [7] | See above. 
Diastolic notch + AFP Total ----- 99.02 7.84 8.00 0.93 
Bilateral diastolic notches + AFP Total ----- 99.57 5.88 13.67 0.95 
Ay E et al, 2005 [9] | See above. 
Doppler + AFP Not available 
Spencer K et al, 2006 [44] | “screening can be improved by combining (…) Doppler scan with (…) biochemical analysis” 
M-PI + Inhibin A Total 0.913 90.0 75.0 7.50 0.28 
M-PI + Activin A Total 0.935 90.0 75.0 7.50 0.28 
Aquilina J et al, 2001 [5] | “statistically significant improvement in the screening efficacy (…) when (…) Doppler studies (…) 
are combined with inhibin-A” 
M-RI + Diastolic notch + Inhibin A Early§ ----- 97.0 60.0 20.00 0.41 
Total ----- 93.4 71.4 10.82 0.31 
Inhibin A followed by Doppler in 53% with highest risk Early§ ----- 93.0 73.0 10.43 0.29 
Total ----- 93.0 70.0 10.00 0.32 
Ay E et al, 2005 [9] | See above. 
Diastolic notch + Inhibin A Total ----- 100.0 71.4   0.29 
RI + Inhibin A Total ----- 100.0 71.4   0.29 
Diastolic notch or high inhibin A Total ----- 93.9 85.7 14.05 0.15 
High RI or high inhibin A Total ----- 82.9 78.6 4.60 0.26 
Florio P et al, 2003 [16] | “activin A and inhibin A (…) may add significant prognostic information for predicting pre-eclampsia 
among women with specific Doppler alterations” 
Inhibin A, in women with diastolic notches Total 0.555 92.0 39.0 4.88 0.66 
Ay E et al, 2005 [9] | See above. 
Diastolic notch + Activin A Total ----- 100.0 78.6   0.21 
Diastolic notch or high activin A Total ----- 86.0 100.0 7.14 0.00 
Florio P et al, 2003 [16] | See above. 
Activin A, in women with diastolic notches Total 0.678 89.0 61.0 5.55 0.44 
Spencer K et al, 2007 [40] | “combining (…) Doppler with (…) PP13 (…) did not improve detection” 
M-PI + PP13 Early‡ 0.930 80.0 100.0 5.00 0.00 
Late 0.620 80.0 29.0 1.45 0.89 
Parra M et al, 2005 [28] | “Doppler is the best predictor of PE and none of biochemical markers significantly improved its 
capacity to screen” 
M-PI + PlGF Not available 
Espinoza J et al, 2007 [15] | “[the addition of PlGF to UAD] improved the positive predictive value (…) without a significant 
reduction in the sensitivity” 
M-PI + Bilateral diastolic notches + PlGF Early ----- 96.4 73.3 20.36 0.28 
Total ----- 96.4 27.3 7.58 0.75 
Stepan H et al, 2007 [46] | “measurement of angiogenic factors has a useful predictive power when used in a risk group and 
focused to severe and early presenting forms of preeclampsia” 
PlGF 
in women with M-PI>1.45 and/or bilateral diastolic notches 
Early ----- 62.0 83.0 2.18 0.27 
Total ----- 62.0 77.0 2.03 0.37 
  
M-PI + PlGF 
in women with M-PI>1.45 and/or bilateral diastolic notches 
Early ----- 76.0 83.0 3.46 0.22 
Total ----- 68.0 77.0 2.41 0.34 
Diab AE et al, 2008 [14] | “We found (…) angiogenic factors to be highly predictive in (…) women with high-risk pregnancies” 
PlGF 
in women with M-PI>1.45 and/or bilateral diastolic notches 
Early 0.904 76.0 100.0 4.17 0.00 
Total 0.897 81.0 88.0 4.63 0.15 
Parra M et al, 2005 [28] | See above. 
M-PI + sFlt-1 Not available 
Espinoza J et al, 2007 [15] | “[sFlt1] did not improve the diagnostic indices of an abnormal [UAD]” 
M-PI + Bilateral diastolic notches + sFlt1 Not available 
Stepan H et al, 2007 [46] | See above. 
sFlt1 
in women with M-PI>1.45 and/or bilateral diastolic notches 
Early ----- 89.0 67.0 6.09 0.37 
Total ----- 70.0 62.0 2.07 0.54 
M-PI + sFlt1 
in women with M-PI>1.45 and/or bilateral diastolic notches 
Early ----- 89.0 83.0 7.55 0.19 
Total ----- 73.0 77.0 2.85 0.32 
Diab AE et al, 2008 [14] | See above. 
sFlt1 
in women with M-PI>1.45 and/or bilateral diastolic notches 
Early 0.956 87.0 100.0 7.69 0.00 






Plasencia W et al, 2008 [31] | “the ratio of uterine artery PI (…) improved significantly the prediction of pre-eclampsia” 
M-PI (T1) + Ratio M-PI (T2/T1) + Maternal history Early 0.983 90.0 100.0 10.00 0.00 
Late 0.783 90.0 46.5 4.65 0.59 
M-PI (T1) + Maternal history  
followed by Ratio M-PI (T2/T1) in 20% with highest risk 
Early ----- 90.0 95.5 9.55 0.05 
Late ----- 90.0 43.7 4.37 0.63 
Spencer K et al, 2005 [43] | “The detection rate (…) in screening by (…) Doppler is improved by the inclusion of (…) PAPP-A” 
M-PI (T2) + PAPP-A (T1) Total 0.853 95.0 62.1 12.42 0.40 
Spencer K et al, 2007 [41] | “both PP-13 and PAPP-A when coupled with (…) PI (…) improve prediction over (…) Doppler 
(…) alone” 
M-PI (T2) + PAPP-A (T1) Early‡ 0.860 80.0 76.0 3.80 0.30 
Late 0.810 80.0 70.0 3.50 0.38 
 Spencer K et al, 2005 [43] | “levels of free β-hCG were not significantly altered in pregnancies that developed complications” 
M-PI (T2) + hCG (T1) Not available 
Spencer K et al, 2008 [42] | “When combined [inhibin-A and activin-A] with (…) PI some improvement (…) could be observed” 
| “the predictive model was no better at identifying early- from late-onset pre-eclampsia” 
M-PI (T2) + Inhibin A (T1) Total ----- 95.0 67.5 13.50 0.34 
Yu J et al, 2010 [50] | “inhibin A, activin A, PIGF and (…) PI may add further information for prediction of pre-eclampsia” 
M-PI (T2) + Inhibin A (T1-T2) Total 0.813 90.0 47.0 4.70 0.59 
Spencer K et al, 2008 [42] | See above. 
M-PI (T2) + Activin A (T1) Total ----- 95.0 63.2 12.64 0.39 
Yu J et al, 2010 [50] | See above. 
M-PI (T2) + Activin A (T1-T2) Total 0.852 90.0 57.0 5.70 0.48 
Spencer K et al, 2007 [41] | See above. 
M-PI (T2) + PP13 (T1) Early‡ 0.900 80.0 79.0 3.95 0.26 
Late 0.790 80.0 70.0 3.50 0.38 
Yu J et al, 2010 [50] | See above. 
M-PI (T2) + PlGF (T1-T2) Total 0.880 90.0 73.0 7.30 0.30 
PE: pre-eclampsia; UAD: uterine artery Doppler; AUC: area under the ROC curve; Sp: specificity; Sn: sensitivity; LR+: likelihood ratio of the 
positive result; LR-: likelihood ratio of the negative result; PI: pulsatility index; L-PI: lowest PI; M-PI: mean PI; H-PI: highest PI; RI: resistance 
index; M-RI: mean RI; PAPP-A: pregnancy-associated plasma protein-A; hCG: human chorionic gonadotropin; AFP: alpha-fetoprotein; PP13: 
placental protein 13; PlGF: placental growth factor; sFlt1: soluble fms-like tyrosine kinase 1; T1: first trimester; T2: second trimester. 
Unless otherwise specified, early PE refers to PE requiring delivery before 34 weeks’ gestation and late PE refers to PE requ iring delivery at or 
after 34 weeks’ gestation. *PE diagnosed before 34 weeks’ gestation. †PE requiring delivery before 32 weeks’ gestation. ‡PE requiring delivery 
before 35 weeks’ gestation. §PE requiring delivery before 37 weeks’ gestation. 
Table 5 – Screening for PE with UAD and two other markers. 




Poon LC et al, 2009/2010 [34,36,37] | Early PE: “significant contributions from PAPP-A (…) maternal factors, MAP and (…) 
L-PI” | Late PE: “prediction from the combination of maternal factors (…) L-PI and MAP (…) was not improved by addition of 
PAPP-A” 
L-PI + Maternal history + MAP Early 0.954 90.0 89.2 8.92 0.12 
Late 0.863 90.0 57.0 5.70 0.48 
L-PI + Maternal history + PAPP-A  Early 0.925 90.0 81.1 8.11 0.21 
Pilalis A et al, 2007 [29] | “We found increased (…) PI and maternal history (…) but not PAPP-A (…) to be independent risk 
factors for pre-eclampsia” 
M-PI + Maternal history + PAPP-A  Not available 
Poon LC et al, 2009 [35] | Early PE: “[AUC] was significantly higher in screening by history with (…) PI than by history alone 
(…) but there was no further improvement in screening if (…) PAPP-A was included” | Late PE: “[AUC] was not significantly 
higher for screening by history with (…) PI than by history alone (…), or by history with serum PAPP-A than by history alone” 
M-PI + Maternal history + PAPP-A  Early 0.905 90.0 71.9 7.19 0.31 
Akolekar R et al, 2009 [1] | “Maternal plasma inhibin A in combination with (…) the maternal history and (…) PI could 
provide effective first-trimester screening” 
M-PI + Maternal history + Inhibin A  Early 0.938 90.0 88.5 8.85 0.13 
Late 0.823 90.0 42.1 4.21 0.64 
Akolekar R et al, 2009 [2] | Early PE: “PP13 (…) did provide significant contribution to prediction” but it “did not improve 
the detection achieved by the combination of maternal factors, (…) L-PI and (…) PAPP-A” | Late PE: “PP13 (…) was not 
significantly different from controls and therefore did not add value in screening” 
L-PI + Maternal history + PP13 Early 0.924 90.0 77.1 7.71 0.25 
Akolekar R et al, 2008 [3] | Early PE: “significant contributions (…) from maternal factors, PlGF, PAPP-A and (…) PI” | Late 
PE: “significant contributions (…) from maternal factors, PlGF and (…) PI but not PAPP-A” 
M-PI + Maternal history + PlGF  Early 0.941 90.0 89.7 8.97 0.11 




Onwudiwe N et al, 2008 [26] | “maternal characteristics, (…) PI and (…) MAP provided significant independent contribution” 
M-PI + Maternal history + MAP 
 
Early 0.996 90.0 100.0 10.00 0.00 
Late 0.830 90.0 56.4 5.64 0.48 
Spencer K et al, 2007 [40] |“combining (…) Doppler with (…)PP13 or PAPP-A or all three together did not improve detection” 
M-PI + PAPP-A + PP13  Early* 0.880 80.0 80.0 4.00 0.25 
Late 0.610 80.0 43.0 2.15 0.71 
Alkazaleh F et al, 2006 [4] | “these ultrasound tests [including UAD] did not identify women at greater (…) risk of severe 
preeclampsia” 
M-PI, in women with hCG>2.5 MoM and AFP>2.0 MoM Severe† ----- 49.0 69.0 1.35 0.63 
Spencer K et al, 2007 [40] | “combination [of PP13] with other biochemical or ultrasound markers did not improve the 
detection” 
M-PI + hCG + PP13  Early* 0.930 80.0 100.0 5.00 0.00 
Late 0.580 80.0 14.0 0.70 1.08 
Spencer K et al, 2006 [44] | “screening can be improved by combining (…) Doppler scan with (…) biochemical analysis” 
M-PI + Inhibin A + Activin A Total 0.970 90.0 92.0 9.20 0.09 
Florio P et al, 2003 [16] | “combining both hormones may improve the predictive value of the test” 
Inhibin A + Activin A, in women with diastolic notches Total ----- 97.5 33.3 13.32 0.68 
High inhibin A or activin A, in women with diastolic 
notches 
Total ----- 72.5 66.7 2.43 0.46 
Spencer K et al, 2007 [40] | See above. 
M-PI + Inhibin A + PP13  Early* 0.910 80.0 100.0 5.00 0.00 
Late 0.550 80.0 29.0 1.45 0.89 
M-PI + Activin A + PP13  Early* 0.920 80.0 100.0 5.00 0.00 
Late 0.840 80.0 71.0 3.55 0.36 
  
Stepan H et al, 2007 [46] | “measurement of angiogenic factors has a useful predictive power when used in a risk group and 
focused to severe and early presenting forms of preeclampsia” 
sFlt1/PlGF ratio 
in women with M-PI>1.45 and/or bilateral diastolic notches 
Early ----- 51.0 67.0 1.37 0.65 
Total ----- 51.0 62.0 1.27 0.75 
sFlt1 + PlGF 
in women with M-PI>1.45 and/or bilateral diastolic notches 
Early ----- 95.0 83.0 16.60 0.18 
Total ----- 73.0 77.0 2.85 0.32 
Diab AE et al, 2008 [14] | “We found (…) angiogenic factors to be highly predictive in (…) women with high-risk pregnancies” 
sFlt1/PlGF ratio 
in women with M-PI>1.45 and/or bilateral diastolic notches 
Early 0.959 90.0 100.0 10.00 0.00 






Spencer K et al, 2007 [41] | “the use of all three markers had no advantage over using just two of them” 
M-PI (T2) + PAPP-A (T1) + PP13 (T1)  Early* 0.850 80.0 70.0 3.50 0.38 
Late 0.820 80.0 73.0 3.65 0.34 
Yu J et al, 2010 [50] | “The combination of activin A, inhibin A and (…) PI or activin A, PIGF and (…) PI provided a test with 
high sensitivity and specificity” 
M-PI (T2) + Inhibin A (T1-T2) + Activin A (T1-T2) Total 0.907 90.0 83.0 8.30 0.19 
M-PI (T2) + Inhibin A (T1-T2) + PlGF (T1-T2) Total 0.840 90.0 66.0 6.60 0.38 
M-PI (T2) + Activin A (T1-T2) + PlGF (T1-T2) Total 0.925 90.0 84.0 8.40 0.18 
PE: pre-eclampsia; UAD: uterine artery Doppler; AUC: area under the ROC curve; Sp: specificity; Sn: sensitivity; LR+: likelihood ratio of the 
positive result; LR-: likelihood ratio of the negative result; PI: pulsatility index; L-PI: lowest PI; M-PI: mean PI; MAP: mean arterial pressure; 
PAPP-A: pregnancy-associated plasma protein-A; hCG: human chorionic gonadotropin; AFP: alpha-fetoprotein; PP13: placental protein 13; PlGF: 
placental growth factor; soluble fms-like tyrosine kinase 1; T1: first trimester; T2: second trimester.  
Unless otherwise specified, early PE refers to PE requiring delivery before 34 weeks’ gestation and late PE refers to PE requiring delivery at or 




Table 6 – Screening for PE with UAD and three other markers. 




Poon LC et al, 2009/2010 [34,36,37] | Early PE: “significant contributions from PAPP-A (…) maternal factors, MAP and (…) 
L-PI” | Late PE: “prediction from the combination of maternal factors (…) L-PI and MAP (…) was not improved by addition of 
PAPP-A” 
L-PI + Maternal history + MAP + PAPP-A  Early 0.960 90.0 94.6 9.46 0.06 
Poon LC et al, 2009 [33] | Early PE: “significant contributions from maternal factors, (…) PI, MAP, PAPP-A, and PlGF” | 
Late PE: “significant contributions from maternal factors, (…) PI, MAP, and PlGF but not PAPP-A” 
M-PI + Maternal history + MAP + PlGF  Early ----- 95.0 82.8 16.56 0.18 
 Late ----- 95.0 44.9 8.98 0.58 
Akolekar R et al, 2009 [2] | Early PE: “PP13 (…) did provide significant contribution to prediction” but it “did not improve 
the detection achieved by the combination of maternal factors, (…) L-PI and (…) PAPP-A” | Late PE: “PP13 (…) was not 
significantly different from controls and therefore did not add value in screening” 
L-PI + Maternal history + PAPP-A + PP13 Not available 
Audibert F et al, 2010 [8] | “the addition of Doppler did not improve the diagnostic accuracy of screening by clinical 
characteristics alone or combined with PAPP-A, PlGF and Inhibin A” 
L-PI + Maternal history + PAPP-A + Inhibin A Early* 0.834 90.0 37.5 3.75 0.69 
 Total 0.745 90.0 32.4 3.24 0.75 
Akolekar R et al, 2009 [1] | Early PE: “significant contributions from (…) PI (…) PAPP-A (…) inhibin A (…)” and maternal 
history | Late PE: “significant contributions from (…) PI (…) inhibin A” and maternal history “but not from (…) PAPP-A” 
M-PI + Maternal history + PAPP-A + Inhibin A  Early 0.938 90.0 88.5 8.85 0.13 
Akolekar R et al, 2008 [3] | Early PE: “significant contributions (…) from maternal factors, PlGF, PAPP-A and (…) PI” | Late 
PE: “significant contributions (…) from maternal factors, PlGF and (…) PI but not PAPP-A” 






Yu J et al, 2010 [50] | “Combination of the three serum markers [inhibin A, activin A, PIGF] and (…) PI has a higher 
prediction value” 
M-PI (T2) + Inhibin A (T1-T2) + Activin A (T1-T2) + 
PlGF (T1-T2) 
Total 0.941 90.0 90.0 9.00 0.11 
PE: pre-eclampsia; UAD: uterine artery Doppler; AUC: area under the ROC curve; Sp: specificity; Sn: sensitivity; LR+: likelihood ratio of the 
positive result; LR-: likelihood ratio of the negative result; PI: pulsatility index; L-PI: lowest PI; M-PI: mean PI; MAP: mean arterial pressure; 
PAPP-A: pregnancy-associated plasma protein-A; PP13: placental protein 13; PlGF: placental growth factor; T1: first trimester; T2: second 
trimester. 
Unless otherwise specified, early PE refers to PE requiring delivery before 34 weeks’ gestation and late PE refers to PE requiring delivery at or 
after 34 weeks’ gestation. *PE diagnosed before 34 weeks’ gestation. 
 
  
Table 7 – Screening for PE with UAD and four other markers. 




Poon LC et al, 2009 [33] | Early PE: “significant contributions from maternal factors, (…) PI, MAP, PAPP-A, and PlGF” | 
Late PE: “significant contributions from maternal factors, (…) PI, MAP, and PlGF but not PAPP-A”  
M-PI + Maternal history + MAP + PAPP-A + PlGF 
 
Early ----- 95.0 93.1 18.62 0.07 
Late ----- 95.0 35.7 7.14 0.68 
Audibert F et al, 2010 [8] | “the addition of Doppler did not improve the diagnostic accuracy of screening by clinical 
characteristics alone or combined with PAPP-A, PlGF, and Inhibin-A” 
L-PI + Maternal history + PAPP-A + Inhibin A + PlGF Early* 0.994 90.0 100.0 10.00 0.00 
Total 0.815 90.0 40.0 4.00 0.67 
PE: pre-eclampsia; UAD: uterine artery Doppler; AUC: area under the ROC curve; Sp: specificity; Sn: sensitivity; LR+: likelihood ratio of the 
positive result; LR-: likelihood ratio of the negative result; PI: pulsatility index; L-PI: lowest PI; M-PI: mean PI; MAP: mean arterial pressure; 
PAPP-A: pregnancy-associated plasma protein-A; PlGF: placental growth factor. 
Unless otherwise specified, early PE refers to PE requiring delivery before 34 weeks’ gestation and late PE refers to PE requiring delivery at or 
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 Trimester Screening 
UAD + 1 other marker 
M-PI + PP1325 
M-PI followed by PP1325 
PP13 followed by M-PI25 
UAD + 2 other markers 
UAD + 3 other markers 
L-PI + History + MAP34,36,37 
M-PI + History + Inhibin A1 
M-PI + History + PlGF3 
L-PI + History + MAP + PAPP-A34,36,37 
M-PI + History + MAP + PlGF33 
M-PI + History + PAPP-A + Inhibin A1 
M-PI + History + PAPP-A + PlGF3 
UAD + 4 other markers 
M-PI + History + MAP  
+ PAPP-A + PlGF*
33 
L-PI + History + PAPP-A  
+ Inhibin A + PlGF†
8 
UAD + 1 other marker 
M-PI + Bilateral diastolic notches 
+ History49 
M-PI + PP1340 
sFlt114 
in women with M-PI>1.45 
and/or bilateral diastolic notches 
M-PI + sFlt146 
in women with M-PI>1.45 
and/or bilateral diastolic notches 
 
UAD + 2 other markers 
M-PI + History + MAP†
26 
M-PI + hCG + PP1340 
M-PI + Inhibin A + PP1340 
M-PI + Activin A + PP1340 
sFlt1 + PlGF46 
in women with M-PI>1.45 
and/or bilateral diastolic notches 
sFlt1/PlGF ratio†
14 
in women with M-PI>1.45 





UAD + 1 other marker 
M-PI (T1) + Ratio M-PI (T2/T1) 
+ History†
31 
M-PI (T1) + History31 
followed by Ratio M-PI (T2/T1) 
Figure 3 – Screening tests which provided moderate or convincing prediction of early PE, according to 
the likelihood ratio (LR) values. 
 
PE: pre-eclampsia; UAD: uterine artery Doppler; PI: pulsatility index; L-PI: lowest PI; M-PI: mean PI; MAP: mean arterial pressure; PAPP-A: pregnancy-
associated plasma protein-A; hCG: human chorionic gonadotropin; PP13: placental protein 13; PlGF: placental growth factor; sFlt1: soluble fms-like 
tyrosine kinase 1; T1: first trimester; T2: second trimester. 
*LR+ > 10 and LR- < 0.1. 























 Trimester Screening 
UAD + 1 other marker 
Diastolic notch or high inhibin A9 
Diastolic notch or high activin A9 
sFlt114 
in women with M-PI>1.45 
and/or bilateral diastolic notches 
UAD + 2 other markers 
M-PI + Inhibin A + Activin A44 
sFlt1/PlGF ratio14 
in women with M-PI>1.45 
and/or bilateral diastolic notches 
 
UAD + 2 other markers 
M-PI (T2) + Inhibin A (T1-T2) + 
Activin A (T1-T2)50 
M-PI (T2) + Activin A (T1-T2) + 
PlGF (T1-T2)50 
UAD + 3 other markers 
M-PI (T2) + Inhibin A (T1-T2) + 




Figure 4 – Screening tests which provided moderate or convincing prediction of total PE, according to the 
likelihood ratio (LR) values. 
 
 
PE: pre-eclampsia; UAD: uterine artery Doppler; PI: pulsatility index; M-PI: mean PI; PlGF: placental growth factor; sFlt1: soluble fms-like tyrosine kinase 
1; T1: first trimester; T2: second trimester. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
